HALO logo

Halozyme Therapeutics (HALO) Working Capital

Annual Working Capital

$946.24 M
+$312.31 M+49.27%

December 31, 2024


Summary


Performance

HALO Working Capital Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherHALObalance sheetmetrics:

Quarterly Working Capital

N/A

December 31, 2024


Summary


Performance

HALO Quarterly Working Capital Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

Earnings dates

OtherHALObalance sheetmetrics:

Working Capital Formula

Working Capital = Current Assets − Current Liabilities

HALO Working Capital Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+49.3%-
3 y3 years+16.9%-
5 y5 years+106.7%-

HALO Working Capital Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-yearat high+55.6%
5 y5-yearat high+609.4%
alltimeall timeat high>+9999.0%

Halozyme Therapeutics Working Capital History

DateAnnualQuarterly
Dec 2024
$946.24 M(+49.3%)
-
Sep 2024
-
$1.02 B(+19.2%)
Jun 2024
-
$854.44 M(+15.2%)
Mar 2024
-
$741.95 M(+17.0%)
Dec 2023
$633.93 M(+4.2%)
$633.93 M(-17.0%)
Sep 2023
-
$763.82 M(+17.6%)
Jun 2023
-
$649.35 M(+24.1%)
Mar 2023
-
$523.10 M(-14.0%)
Dec 2022
$608.22 M(-24.8%)
$608.22 M(+11.8%)
Sep 2022
-
$543.82 M(+58.8%)
Jun 2022
-
$342.43 M(-61.0%)
Mar 2022
-
$877.00 M(+8.4%)
Dec 2021
$809.14 M(+506.6%)
$809.14 M(-10.5%)
Sep 2021
-
$904.15 M(+2.1%)
Jun 2021
-
$885.50 M(+6.1%)
Mar 2021
-
$834.30 M(+525.5%)
Dec 2020
$133.38 M(-70.9%)
$133.38 M(-71.7%)
Sep 2020
-
$471.92 M(-0.5%)
Jun 2020
-
$474.29 M(+11.3%)
Mar 2020
-
$425.97 M(-7.0%)
Dec 2019
$457.80 M(+64.4%)
$457.80 M(+95.6%)
Sep 2019
-
$234.00 M(-8.7%)
Jun 2019
-
$256.29 M(-5.2%)
Mar 2019
-
$270.37 M(-2.9%)
Dec 2018
$278.49 M(-26.5%)
$278.49 M(-4.2%)
Sep 2018
-
$290.81 M(-11.8%)
Jun 2018
-
$329.60 M(-9.8%)
Mar 2018
-
$365.25 M(-3.6%)
Dec 2017
$379.04 M(+87.7%)
$379.04 M(+50.8%)
Sep 2017
-
$251.30 M(-2.7%)
Jun 2017
-
$258.22 M(+60.7%)
Mar 2017
-
$160.65 M(-20.5%)
Dec 2016
$201.95 M(+84.7%)
$201.95 M(-8.2%)
Sep 2016
-
$219.94 M(-10.4%)
Jun 2016
-
$245.46 M(+5.4%)
Mar 2016
-
$232.81 M(+113.0%)
Dec 2015
$109.31 M(-20.2%)
$109.31 M(+1.0%)
Sep 2015
-
$108.24 M(-18.9%)
Jun 2015
-
$133.40 M(+4.9%)
Mar 2015
-
$127.12 M(-7.2%)
Dec 2014
$136.99 M(+94.9%)
$136.99 M(+10.5%)
Sep 2014
-
$124.01 M(-13.8%)
Jun 2014
-
$143.90 M(-6.9%)
Mar 2014
-
$154.55 M(+119.9%)
Dec 2013
$70.29 M
$70.29 M(+11.2%)
DateAnnualQuarterly
Sep 2013
-
$63.19 M(-6.5%)
Jun 2013
-
$67.59 M(-26.0%)
Mar 2013
-
$91.36 M(-18.2%)
Dec 2012
$111.68 M(+139.2%)
$111.68 M(+32.0%)
Sep 2012
-
$84.58 M(-18.3%)
Jun 2012
-
$103.58 M(-10.6%)
Mar 2012
-
$115.89 M(+148.2%)
Dec 2011
$46.69 M(-37.0%)
$46.69 M(-26.1%)
Sep 2011
-
$63.18 M(+11.9%)
Jun 2011
-
$56.47 M(-15.2%)
Mar 2011
-
$66.59 M(-10.2%)
Dec 2010
$74.16 M(+23.5%)
$74.16 M(-14.4%)
Sep 2010
-
$86.65 M(+126.5%)
Jun 2010
-
$38.26 M(-21.8%)
Mar 2010
-
$48.92 M(-18.5%)
Dec 2009
$60.04 M(+0.4%)
$60.04 M(-11.2%)
Sep 2009
-
$67.59 M(-13.9%)
Jun 2009
-
$78.48 M(+48.5%)
Mar 2009
-
$52.85 M(-11.6%)
Dec 2008
$59.79 M(-35.2%)
$59.79 M(-11.0%)
Sep 2008
-
$67.17 M(-12.4%)
Jun 2008
-
$76.71 M(-11.8%)
Mar 2008
-
$87.02 M(-5.7%)
Dec 2007
$92.31 M(+123.3%)
$92.31 M(-7.5%)
Sep 2007
-
$99.81 M(+3.0%)
Jun 2007
-
$96.94 M(+42.3%)
Mar 2007
-
$68.14 M(+64.8%)
Dec 2006
$41.34 M(+132.2%)
$41.34 M(+183.7%)
Sep 2006
-
$14.57 M(+3.9%)
Jun 2006
-
$14.03 M(-11.7%)
Mar 2006
-
$15.89 M(-10.8%)
Dec 2005
$17.80 M(+22.2%)
$17.80 M(+247.3%)
Sep 2005
-
$5.13 M(-42.0%)
Jun 2005
-
$8.83 M(-24.0%)
Mar 2005
-
$11.61 M(-20.3%)
Dec 2004
$14.57 M(>+9900.0%)
$14.57 M(+799.5%)
Sep 2004
-
$1.62 M(-65.8%)
Jun 2004
-
$4.73 M(-30.3%)
Mar 2004
-
$6.80 M(>+9900.0%)
Sep 2003
-
$60.90 K(-10.2%)
Jun 2003
-
$67.80 K(-12.5%)
Mar 2003
-
$77.50 K(-27.7%)
Sep 2002
-
$107.20 K(-10.1%)
Jun 2002
-
$119.20 K(+263.4%)
Mar 2002
-
$32.80 K
Dec 2001
$22.80 K
-

FAQ

  • What is Halozyme Therapeutics annual working capital?
  • What is the all time high annual working capital for Halozyme Therapeutics?
  • What is Halozyme Therapeutics annual working capital year-on-year change?
  • What is the all time high quarterly working capital for Halozyme Therapeutics?

What is Halozyme Therapeutics annual working capital?

The current annual working capital of HALO is $946.24 M

What is the all time high annual working capital for Halozyme Therapeutics?

Halozyme Therapeutics all-time high annual working capital is $946.24 M

What is Halozyme Therapeutics annual working capital year-on-year change?

Over the past year, HALO annual working capital has changed by +$312.31 M (+49.27%)

What is the all time high quarterly working capital for Halozyme Therapeutics?

Halozyme Therapeutics all-time high quarterly working capital is $1.02 B